Bcr-Abl
Les inhibiteurs de Bcr-Abl sont des thérapies ciblées qui inhibent la protéine de fusion Bcr-Abl, formée à la suite de la translocation du chromosome Philadelphie et moteur de la leucémie myéloïde chronique (LMC). Cette protéine influence également l'angiogenèse, contribuant à la progression tumorale. Les inhibiteurs de Bcr-Abl sont cruciaux dans le traitement de la LMC et sont explorés pour leur potentiel à inhiber l'angiogenèse dans divers cancers. Chez CymitQuimica, nous offrons des inhibiteurs de Bcr-Abl de haute qualité pour soutenir vos recherches en biologie du cancer, angiogenèse et thérapies ciblées.
129 produits trouvés pour "Bcr-Abl".
Filtrer par
Pourcentage de pureté
0
100
|
0
|
50
|
90
|
95
|
100
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
Imatinib Mesylate
CAS :Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR,Formule :C29H31N7O·CH4SO3Degré de pureté :98% - >99.99%Couleur et forme :White SolidMasse moléculaire :589.71Dasatinib
CAS :Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive.Formule :C22H26ClN7O2SDegré de pureté :99.59% - 99.86%Couleur et forme :Pale-Yellow SolidMasse moléculaire :488.006Lyn-IN-1
CAS :Lyn-IN-1 (Bafetinib analog) is a selective and potent dual inhibitor of Bcr-Abl and LynFormule :C30H31F3N8ODegré de pureté :98.02% - 98.77%Couleur et forme :SolidMasse moléculaire :576.6153Imatinib impurities3
CAS :Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.Formule :C24H20ClN5ODegré de pureté :98.63%Couleur et forme :SolidMasse moléculaire :429.902LXH254
CAS :LXH254 is a B/C RAF inhibitor with IC50 values of 0.2 nM and 0.07 nM for inhibiting BRAF and CRAF.Cost-effective and quality-assured.Formule :C25H25F3N4O4Degré de pureté :98.30% - 99.92%Couleur et forme :White SolidMasse moléculaire :502.4856N-Desmethyl imatinib
CAS :N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.Formule :C28H29N7ODegré de pureté :98.60%Couleur et forme :SolidMasse moléculaire :479.5762Bosutinib
CAS :Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.Formule :C26H29Cl2N5O3Degré de pureté :98.98% - 99.96%Couleur et forme :Yellow SolidMasse moléculaire :530.446Dasatinib monohydrate
CAS :Dasatinib monohydrate, an oral SRC-kinase inhibitor, counters imatinib-resistant chronic myeloid leukemia.Formule :C22H28ClN7O3SDegré de pureté :99.68% - >99.99%Couleur et forme :White SolidMasse moléculaire :506.03Nilotinib
CAS :Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor. Nilotinib has antitumor activity and may be used in CML. Cost-effective and quality-assured.Formule :C28H22F3N7ODegré de pureté :99.89% - >99.99%Couleur et forme :SolidMasse moléculaire :529.52AKE-72
CAS :AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.Formule :C30H29F3N6ODegré de pureté :99.91%Couleur et forme :SolidMasse moléculaire :546.59SIAIS056
CAS :SIAIS056 is a BCR-ABL PROTAC degrader with a DC50 value of 0.18 nM. It inhibits the BCR-ABL signaling pathway in a time-dependent manner in K562 cells and reduces the phosphorylation levels of BCR-ABL and its downstream molecules, STAT5 and CRKL. SIAIS056 can induce the degradation of various clinically relevant BCR-ABL resistant mutants and exhibits antiproliferative activity against K562 and 32D-BCR-ABL cells. Additionally, it can cause significant tumor regression in K562 xenograft models and is applicable for leukemia research.Formule :C35H34ClN9O5S2Masse moléculaire :760.29SNIPER(ABL)-020
SNIPER(ABL)-020, a Dasatinib-Bestatin conjugate via linker, inhibits ABL and targets IAP, reducing BCR-ABL protein.Formule :C44H59ClN10O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :923.52FDA-Approved Kinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Couleur et forme :LiquidKinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Couleur et forme :Odour SolidP19As
CAS :P19As is a BCR-ABL PROTAC degrader based on Asciminib, with a DC50 of approximately 200 nM for the wild-type BCR-ABL protein. It is capable of degrading the T315I mutant and demonstrates strong antiproliferative activity in BaF3-BCR-ABL (T315I) cells. P19As is applicable for research in chronic myeloid leukemia and acute lymphoblastic leukemia.Formule :C47H51ClF2N12O10Masse moléculaire :1017.45SNIPER(ABL)-019
SNIPER(ABL)-019, a compound that links Dasatinib (ABL inhibitor) to MV-1 (IAP ligand) via a linker, effectively reduces BCR-ABL protein levels, exhibiting aFormule :C60H77ClN12O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1177.85FGFRs-IN-1
FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.Formule :C28H26Cl2N4O3Couleur et forme :SolidMasse moléculaire :537.44PROTAC BCR-ABL1 ligand 1
CAS :GMB-475 is a PROTAC ligand targeting BCR-ABL1 for degradation via E3 ligase recruitment.Formule :C17H12F3N3O2Couleur et forme :SolidMasse moléculaire :347.29ML 2-23
ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].Formule :C47H53BrCl2N10O7SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1052.86DPH
CAS :DPH is a potent cell permeable activator of c-Abl. It shows potent enzymatic and cellular activity in stimulating c-Abl activation.Formule :C18H13FN4O2Degré de pureté :99.65%Couleur et forme :SolidMasse moléculaire :336.3198
